Skip to main content

Table 2 Comparison of baseline characteristics in the unmatched and the matched data

From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Characteristics Unmatched data Matched data
No. (%) No. (%)
AbiRT (N = 30) Non-AbiRT (N = 119) P AbiRT (N = 30) Non-AbiRT (N = 58) P
Age, years    0.224    0.440
 ≤ 65 15 (50.0) 45 (37.8)   15 (50.0) 24 (41.3)  
 > 65 15 (50.0) 74 (62.2)   15 (50.0) 34 (58.6)  
PSA at mCRPC    0.005    0.667
 ≤ 20 ng/mL 23 (76.6) 57 (47.9)   23 (76.6) 42 (72.4)  
 > 20 ng/mL 7 (23.3) 62 (52.1)   7 (23.3) 16 (27.6)  
Gleason score    0.435    0.886
 ≤ 8 16 (53.3) 54 (45.4)   16 (53.3) 30 (51.7)  
 9–10 14 (46.6) 65 (54.6)   14 (46.6) 28 (48.3)  
Prognostic index    0.107    0.227
 Good 17 (56.6) 48 (40.3)   17 (56.6) 25 (43.1)  
 Intermediate/poor 13 (43.3) 71 (59.7)   13 (43.3) 33 (56.9)  
Oligometastasis 19 (63.3) 39 (32.8) 0.002 19 (63.3) 36 (62.1) 0.908
Synchronous metastasis 24 (80.0) 103 (86.6) 0.538 24 (80.0) 48 (82.8) 0.750
Chemo-naïve 28 (93.3) 95 (79.8) 0.082 28 (93.3) 53 (91.4) 1.000
  1. PSA prostate-specific antigen, mCRPC metastatic castration-resistant prostate cancer, Chemo-naïve chemotherapy-naïve upon abiraterone treatment